Regulated Cell Death in Neurodegenerative Disorders

Regulated Cell Death in Neurodegenerative Disorders is a comprehensive exploration of the mechanisms and implications of RCD within the realm of neurodegenerative diseases. The book delves into various forms of RCD such as apoptosis, necroptosis, ferroptosis, pyroptosis, and autophagy-mediated cell death, shedding light on their specific roles in disorders like Alzheimer’s, Parkinson’s, Multiple sclerosis, Amyotrophic lateral sclerosis, and Huntington’s. Written by leading experts, each chapter offers unique insights into cellular demise, providing valuable information on treatment options and therapeutic targets. The book features 14 chapters that cover molecular, cellular, and pharmacological mechanisms from an applied science perspective.

Topics include the importance of chaperones, kinases, growth factors, inflammaging, mitochondrial dynamics, and oxidative stress. It presents targeted strategies to prevent cell death, reflecting ongoing pursuits in understanding and innovating treatments for neurodegenerative diseases. By offering therapeutic strategies to modulate RCD, this book not only shares knowledge but also provides hope for future advancements in combating these debilitating conditions.

• Provides a comprehensive overview of different types of RCD
• Dissects the crosstalk between different types of RCD
• Explores the relevance of RCD mechanisms to neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, Multiple sclerosis, Amyotrophic lateral sclerosis, and Huntington’s disease
• Examines several forms of regulated cell death, including apoptosis, necroptosis, ferroptosis, pyroptosis, and autophagy-mediated cell death
• Discusses the effect of Inflammaging and oxidative stress on different types of RCD
• Delves into the effect of chaperones, kinases, and growth factors on different RCD machinery
• Discusses the potential of targeted therapies aimed at interdicting cell death machineries
• Explores disease-modifying agents targeting RCD in neurodegenerative disorders